The plan to allow insurance reimbursement when switching between JAK inhibitors in rheumatoid arthritis, which was expected to take effect in October, has been postponed.

According to Dailypharm coverage, the health authorities have recently put on hold the notification of the proposed revision that allows switching between JAK inhibitors in rheumatoid arthritis. The tentative timeline for the notification was set as the end of the year, but this is not confirmed yet.

The delay was reportedly caused by problems with the final approval of the budget bill.

Currently, 4 drugs are prescribed for rheumatoid arthritis in Korea, including Pfizer Korea’s Xeljanz (tofacitinib), Lil